Aspirin vs Clopidogrel 1 Month After Acute Coronary Syndrome With High-Bleeding Risk or ST-Segment Elevation

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• High bleeding risk (HBR) and acute coronary syndrome (ACS) subtypes, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS), are crucial for determining optimal antiplatelet therapy.
• Choosing the right antiplatelet strategy is vital for managing ACS patients post-percutaneous coronary intervention (PCI).

Purpose of the Study:

• To compare the 1-year efficacy and safety of aspirin versus clopidogrel in ACS patients undergoing PCI.
• To analyze these effects based on subgroups: high bleeding risk (HBR) vs. non-HBR and STEMI vs. NSTE-ACS.

Main Methods:

• The study analyzed data from the Short and Optimal Duration of Dual Antiplatelet Therapy-3 (STOPDAPT-3) trial.
• Aspirin and clopidogrel monotherapy were compared beyond 30 days up to 1 year post-PCI.
• Coprimary endpoints included cardiovascular events (death, MI, stent thrombosis, stroke) and major bleeding (BARC 3 or 5).

Main Results:

• No statistically significant differences in cardiovascular endpoints were observed between aspirin and clopidogrel in HBR/non-HBR or STEMI/NSTE-ACS subgroups.
• Similarly, bleeding endpoint rates did not differ significantly between the two antiplatelet agents across these patient stratifications.
• Hazard ratios (HRs) for cardiovascular and bleeding endpoints showed no significant interaction with HBR or ACS subtype.

Conclusions:

• Aspirin and clopidogrel demonstrate comparable cardiovascular and bleeding outcomes in ACS patients up to 1 year post-PCI.
• These findings apply irrespective of high bleeding risk (HBR) status or ACS subtype (STEMI/NSTE-ACS).
• The study supports individualized antiplatelet therapy decisions based on patient-specific risk factors.